Results 121 to 130 of about 11,301 (165)

Safety and Efficacy of Achieving Very Low LDL Cholesterol Concentrations with PCSK9 Inhibitors. [PDF]

J Clin Med
Machanahalli Balakrishna A, Kaushik S, Tandalam Palanivelu S, Monther N, Ponamgi SP, Alla VM, Patil SM.   +6 more
europepmc   +1 more source

Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis. [PDF]

J Am Heart Assoc
Zheng Y, Li Q, Yang Y, Yang J, Liu Z, Ma X, Wang Z.   +6 more
europepmc   +1 more source

Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin Intolerance. [PDF]

Eur J Neurol
Theodorou A, Papagiannopoulou G, Akrivaki A, Fanouraki S, Moschovos C, Papadopoulou M, Palaiodimou L, Merkouri F, Melanis K, Salakou S, Kitsos D, Lambadiari V, Zouvelou V, Papadimas G, Giannopoulos S, Alexandrov AV, Tsivgoulis G.   +16 more
europepmc   +1 more source

Modulation of atherogenesis biomarkers by PCSK9 inhibitors in Lp(a)-stimulated human coronary artery endothelial cells. [PDF]

BMC Cardiovasc Disord
Zulkapli R, Muid SA, Wang SM, Putera Mohd Yusof MY, Nawawi H.   +4 more
europepmc   +1 more source

Current and future role of PCSK9 inhibitors in ASCVD prevention. [PDF]

Future Cardiol
Greco A, Capodanno D.
europepmc   +1 more source

Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study. [PDF]

PeerJ
Li Z, Li X, Zhang Y, Qi J, Ji L, Li S, Gu M, Liu Y, Zhang Y, Mei Y, Wang M, Zhou J, Su M, Zhu L, Deng Q.   +14 more
europepmc   +1 more source

PCSK9 Inhibitors or Cardiovascular Disease Inhibitors?

Journal of Cardiology & Cardiovascular Therapy, 2016
openaire   +1 more source

Surface-modified extracellular vesicles take their chance in the big PCSK9 inhibitors' race. [PDF]

Mol Ther
Ben-Aicha S, Emanueli C.
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Novel Therapy in the Treatment of Cholesterol Crystal Embolism-Induced Kidney Injury. [PDF]

Kidney Med
Strimaitis BJ, Francis L, O'Sullivan ED.
europepmc   +1 more source

Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases. [PDF]

Biomedicines
Li Z, Zhu L, Xu Y, Zhang Y, Liu Y, Sun H, Li S, Wang M, Jiang T, Zhou J, Deng Q.   +10 more
europepmc   +1 more source